Omeros (OMER) Net Income towards Common Stockholders (2010 - 2026)
Omeros (OMER) reported Net Income towards Common Stockholders of $4.8 million for Q1 2026, up 17.2% on a YoY basis from $4.1 million in Q1 2025, and down 26.67% sequentially from $6.6 million in Q4 2025.
Omeros (OMER) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Omeros (OMER) has 17 years of Net Income towards Common Stockholders data on file, last reported at $4.8 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 17.2% year-over-year to $4.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 90.69% YoY), and the FY2025 full-year result was $1.5 million, down 94.35% from the prior year.
- Net Income towards Common Stockholders declined to $4.8 million in Q1 2026, from $6.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $174.8 million in Q4 2022 to a low of -$9.7 million in Q3 2025.
- A 5-year average of $18.7 million and a median of $6.6 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Across the five-year window, Net Income towards Common Stockholders soared 73.05% in 2022 and sank 298.2% in 2025, its largest moves.
- Tracing OMER's Net Income towards Common Stockholders over 5 years: stood at $174.8 million in 2022, then slumped by 82.71% to $30.2 million in 2023, then sank by 82.85% to $5.2 million in 2024, then grew by 26.59% to $6.6 million in 2025, then dropped by 26.67% to $4.8 million in 2026.
- Business Quant data shows OMER's Net Income towards Common Stockholders at $4.8 million in Q1 2026, $6.6 million in Q4 2025, and -$9.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Omeros | 707.67 Mn | 707.67 Mn | 9.31 Mn | 4.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.81 Mn |
| Dec 31, 2025 | 6.56 Mn |
| Sep 30, 2025 | -9.67 Mn |
| Jun 30, 2025 | 466,000.00 |
| Mar 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | 5.18 Mn |
| Sep 30, 2024 | 4.88 Mn |
| Jun 30, 2024 | 9.08 Mn |
| Mar 31, 2024 | 6.67 Mn |
| Dec 31, 2023 | 30.22 Mn |
| Sep 30, 2023 | 13.91 Mn |
| Jun 30, 2023 | 7.00 Mn |
| Mar 31, 2023 | 5.98 Mn |
| Dec 31, 2022 | 174.78 Mn |
| Sep 30, 2022 | 37.34 Mn |
| Jun 30, 2022 | 10.85 Mn |
| Mar 31, 2022 | 6.48 Mn |
| Dec 31, 2021 | 328.94 Mn |
| Sep 30, 2021 | 21.58 Mn |
| Jun 30, 2021 | 21.59 Mn |